Ophthalmology

A new analysis presented at ADA 2023 recommended effective diabetic retinopathy screening for patients with T2D and hypertension.

A direct comparison of 3 independent AI systems showed differing prevalences of diabetic retinopathy, suggesting inconsistencies when applying these tools to those without preexisting diabetes.

The analysis, from ADA 2023, additionally indicated SGLT2 inhibition showed no effect on the risk of requiring intravitreal injection treatment for DME.

Use of metformin was associated with significant reductions in the risk of developing POAG beyond glycemic control, according to an analysis presented at ADA 2023.

The letter makes reference to an ongoing review of inspection findings from a third-party filler involved with the drug development. Regeneron will not require additional trial data.

APX3330 showed statistically significant prevention of ≥3-step binocular DRSS worsening compared to placebo, but did not meet the study's primary endpoint.

An analysis presented at ADA 2023 suggests autonomous artificial intelligence testing for diabetic eye diseases promoted health equity across various patient subgroups.

Results from the EMPRISE study presented at ADA 2023 showed empagliflozin was associated with a 23% reduction in the risk of diabetic retinopathy progression in adults with T2D.

A new analysis from ADA 2023 suggests positive discordance according to GMI/A1c ratios was associated with an increased risk for diabetic retinopathy.

According to new data presented at ADA 2023, patients with T2D experience an increased risk of incident retinopathy per 1-SD increase in glycemia risk index.

A new analysis presented at ADA 2023 suggests a machine learning algorithm may refine the risk of diabetic retinopathy progression and personalize screening intervals for patients.

Research presented at ADA 2023 suggests early glycemic screening in high-risk children may predict future diabetes-related complications, including retinopathy and nephropathy.

An analysis provided updated estimates of the US prevalence of DR and VTDR, showing that 9.6 million people had DR and 1.84 million people had VTDR in 2021.

The analysis of the DRCR Retina Network Protocol AC suggested cost savings occur with bevacizumab-first step therapy in eyes with DME, but the magnitude might not be as great as previously understood.

Additional phase 4 trial results presented at ENDO 2023 reinforce the efficacy and safety of teprotumumab-trbw in eyes with TED, regardless of disease activity or duration.

Intravitreal corticosteroid injections improved vision in eyes with persistent or recurrent uveitis-related macular edema better than methotrexate or ranibizumab injections.

Cross-sectional findings from Hong Kong suggest exposure to secondhand smoke presented a dose-dependent association with myopia among children aged 6 to 8 years.

Results from the phase 3 CHAMP trial may support low-dose atropine as a pharmacological treatment option for myopia progression in children.

An analysis in Denmark observed increased adherence and persistence in latanoprost users who switched between different latanoprost formulations.

An analysis of the Ontario Health WTIS database suggests the presence of systematic sex-based differences could be affecting the timeliness of ophthalmic surgery for women.

The biggest predictors of retinal sensitivity loss during 2 years of anti-VEGF treatment included RPE atrophy, Type 2 MNV, cystoid intraretinal spaces, and the presence of SRT.

Intravitreal anti-VEGF injections were associated with an increase in the likelihood of systemic adverse events among patients with diabetic retinopathy.

Each month, our editorial staff compiles a recap of the top news in ophthalmology from the past month. Our May 2023 month-in-review features new FDA approvals, the future of artificial intelligence in eye care, and interesting crossover coverage.

The findings could provide insight into incorporating both OCTA and artificial intelligence for early detection of DMI and better enhancing the management of diabetic retinopathy.

However, trends in the incidence of eye injuries associated with non-powder guns should be interpreted with caution as COVID-19 may have interfered with epidemiological trends.

Announced by Bausch + Lomb and Novaliq, the prescription eye drop for DED is the first and only drop that directly targets tear evaporation, with approval based on results from 2 pivotal phase 3 trials.

Cost-effective smartphone-based fundus imaging systems may be effective for the detection of treatment-requiring ROP, and help increase the global capacity for ROP screening.

A recent analysis suggests that incorporating retinal and choroidal microvascular metrics may improve the identification of eyes with no diabetic retinopathy from those with DR.

A lack of a significant refractive error and visiting an optometrist rather than an ophthalmologist were factors associated with a missed diagnosis of primary open-angle glaucoma, according to a recent analysis.

The use of other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were not clearly associated with glaucoma in a recent analysis.